ACCESS Registry: A Post Market Follow-up Study to Monitor the Safety, Performance and Usability of Occlutech Accessory Medical Devices
Launched by OCCLUTECH INTERNATIONAL AB · Dec 29, 2021
Trial Information
Current as of July 06, 2025
Recruiting
Keywords
ClinConnect Summary
The ACCESS Registry is a study designed to check the safety and performance of certain medical devices made by Occlutech that help doctors implant heart devices. In this study, researchers will collect feedback from healthcare providers about how these accessory devices—the Occlutech Delivery Set, Pistol Pusher, Occlusions-Pusher, and Sizing Balloon—are working during procedures to place heart implants. This is a non-invasive study, meaning participants won’t have to undergo any additional medical procedures just for this study; instead, healthcare providers will fill out surveys about their experiences.
To be eligible for this study, you need to have had a heart implant procedure using one of the Occlutech accessory devices. There are specific guidelines that determine who can participate based on the instructions provided for these devices. This study is currently recruiting participants of all ages and genders. If you take part, you can expect to contribute to important information that helps ensure these devices are safe and effective for patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Inclusion Criteria depend exclusively on the requirements outlined in the applicable Instruction for Use for accessory medical devices and cardiac implant devices.
- • All subjects who underwent implantation procedure with an Occlutech accessory medical device and cardiac implants can be included
- Exclusion Criteria:
- • Exclusion Criteria depend exclusively on the requirements outlined in the applicable Instruction for Use and if applicable in the corresponding protocol of the investigation on the Occlutech implant devices.
About Occlutech International Ab
Occlutech International AB is a pioneering medical device company focused on developing innovative solutions for the treatment of structural heart diseases and vascular conditions. With a commitment to advancing patient care, Occlutech specializes in minimally invasive technologies, including occluders and delivery systems designed to address various cardiovascular challenges. The company is dedicated to rigorous clinical research and development, ensuring that its products meet the highest standards of safety and efficacy. By collaborating with leading healthcare professionals and institutions, Occlutech aims to enhance treatment options and improve outcomes for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kocaeli, , Turkey
Mönchengladbach, , Germany
Adana, Balcalı, Turkey
Malatya, Battalgazi, Turkey
Ankara, Dışkapı, Turkey
Aydın, Efeler, Turkey
Istanbul, Fatih, Turkey
İzmir, Konak, Turkey
Diyarbakır, Sur, Turkey
Gaziantep, şehitkamil, Turkey
Adana, , Turkey
Erlangen, , Germany
Ankara, , Turkey
Ankara, , Turkey
Eskişehir, , Turkey
Eskişehir, , Turkey
Antalya, , Turkey
Antalya, , Turkey
Istanbul, , Turkey
Istanbul, , Turkey
Istanbul, , Turkey
Mersin, , Turkey
Adana, , Turkey
Ankara, , Turkey
Gaziantep, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials